deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT03704688

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions KRAS Gene Mutation Non Small Cell Lung Cancer
Interventions Ponatinib 15 MG Ponatinib 30 MG Trametinib 0.5 mg Trametinib 1 MG Trametinib 1.5 MG Trametinib 2 mg
Updated 13 times since 2018 Last updated: May 8, 2025 Started: Oct 9, 2018 Primary completion: Feb 4, 2022 Completion: Feb 4, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates KRAS Gene Mutation and Non Small Cell Lung Cancer and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Mar 2022 · 10 months · monthly snapshot~Mar 2022 – ~Oct 2023 · 19 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 15 months · monthly snapshot

Change History

13 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Mar 2022 — Oct 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 8 earlier versions

  1. May 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Nov 2019 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. May 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations